Datasheet

生物学的記述

Specificity	TIM-3 Antibody [F19D23] detects endogenous levels of total TIM-3 protein.
Background	TIM-3 (T cell immunoglobulin and mucin-domain containing-3), encoded by HAVCR2, belongs to the TIM family of transmembrane glycoproteins characterized by an N-terminal immunoglobulin variable (IgV) domain with a unique metal-ion dependent ligand (MID-like) binding site framed by FG and CC′ loops, a glycosylated mucin stalk, a transmembrane domain, and a cytoplasmic tail with five conserved tyrosine residues (e.g., Tyr256 and Tyr263) lacking classical inhibitory motifs but enabling interactions with BAT3, FYN, and LCK. Primarily expressed on activated IFN-γ-producing Th1 and CD8+ T cells, TIM-3 acts as a key inhibitory receptor, where ligand binding (galectin-9 to N-glycans on IgV, phosphatidylserine or CEACAM1 to the FG/CC′ pocket) triggers ITK-mediated phosphorylation of cytoplasmic tyrosines, releasing BAT3 to suppress TCR signaling, promote FYN recruitment for T cell anergy, disrupt immunological synapses via CD45/CD148 association, and induce apoptosis, thereby downregulating Th1 responses, enhancing Treg suppression, and limiting autoimmunity while exacerbating exhaustion in chronic infections and cancer. In myeloid cells like DCs and macrophages, TIM-3 binds HMGB1 or PtdSer to dampen TLR-mediated innate immunity (e.g., nucleic acid sensing), promote apoptotic cell phagocytosis for cross-presentation or tolerance, and inhibit proinflammatory cytokines, contributing to tumor immunosuppression. TIM-3 marks terminally exhausted PD-1+ T cells in tumors/viral infections, drives LSC self-renewal in AML via autocrine galectin-9/β-catenin/mTOR/HIF1α pathways, correlates with poor prognosis, and its blockade synergizes with PD-1 inhibition to restore antitumor immunity. Loss-of-function HAVCR2 mutations impair TIM-3 folding/surface expression, causing hyperinflammation and subcutaneous panniculitis-like T-cell lymphoma.

Specificity

TIM-3 Antibody [F19D23] detects endogenous levels of total TIM-3 protein.

Background

TIM-3 (T cell immunoglobulin and mucin-domain containing-3), encoded by HAVCR2, belongs to the TIM family of transmembrane glycoproteins characterized by an N-terminal immunoglobulin variable (IgV) domain with a unique metal-ion dependent ligand (MID-like) binding site framed by FG and CC′ loops, a glycosylated mucin stalk, a transmembrane domain, and a cytoplasmic tail with five conserved tyrosine residues (e.g., Tyr256 and Tyr263) lacking classical inhibitory motifs but enabling interactions with BAT3, FYN, and LCK. Primarily expressed on activated IFN-γ-producing Th1 and CD8+ T cells, TIM-3 acts as a key inhibitory receptor, where ligand binding (galectin-9 to N-glycans on IgV, phosphatidylserine or CEACAM1 to the FG/CC′ pocket) triggers ITK-mediated phosphorylation of cytoplasmic tyrosines, releasing BAT3 to suppress TCR signaling, promote FYN recruitment for T cell anergy, disrupt immunological synapses via CD45/CD148 association, and induce apoptosis, thereby downregulating Th1 responses, enhancing Treg suppression, and limiting autoimmunity while exacerbating exhaustion in chronic infections and cancer. In myeloid cells like DCs and macrophages, TIM-3 binds HMGB1 or PtdSer to dampen TLR-mediated innate immunity (e.g., nucleic acid sensing), promote apoptotic cell phagocytosis for cross-presentation or tolerance, and inhibit proinflammatory cytokines, contributing to tumor immunosuppression. TIM-3 marks terminally exhausted PD-1+ T cells in tumors/viral infections, drives LSC self-renewal in AML via autocrine galectin-9/β-catenin/mTOR/HIF1α pathways, correlates with poor prognosis, and its blockade synergizes with PD-1 inhibition to restore antitumor immunity. Loss-of-function HAVCR2 mutations impair TIM-3 folding/surface expression, causing hyperinflammation and subcutaneous panniculitis-like T-cell lymphoma.

使用情報

Application

WB, IP, IHC

Dilution

WB	IP	IHC
1:1000	1:100	1:200

Reactivity

Mouse

Source

Rabbit Monoclonal Antibody

MW

45-80 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/33931442/
https://pubmed.ncbi.nlm.nih.gov/34159709/

TIM-3 Antibody [F19D23]

生物学的記述

使用情報

References

Application Data